NTRK fusion-positive cancers and TRK inhibitor therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• NTRK gene fusions involving NTRK1, NTRK2, or NTRK3 act as oncogenic drivers in diverse adult and pediatric tumors.
• These fusions encode neurotrophin receptors TRKA, TRKB, and TRKC, crucial in cancer development.

Purpose of the Study:

• To review the biology of NTRK fusions.
• To discuss therapeutic strategies for both treatment-naive and acquired-resistance settings.
• To examine the safety profile of TRK inhibitors.

Main Methods:

• Detection of NTRK fusions using methods like tumor DNA/RNA sequencing and plasma cell-free DNA profiling.
• Treatment of NTRK fusion-positive cancers with first-generation TRK inhibitors (larotrectinib, entrectinib).
• Exploration of second-generation TRK inhibitors (LOXO-195, TPX-0005) for resistance mutations.

Main Results:

• First-generation TRK inhibitors achieve high response rates (>75%) in NTRK fusion-positive cancers, irrespective of histology.
• These inhibitors generally have a well-tolerated safety profile, with some off-tumor, on-target adverse events.
• Acquired resistance to TRK inhibitors can occur due to NTRK kinase domain mutations, which may be overcome by newer agents.

Conclusions:

• NTRK fusions are targetable oncogenic drivers across various tumor types.
• TRK inhibitors offer significant clinical benefit, but acquired resistance necessitates the development of next-generation therapies.
• Understanding NTRK fusion biology and resistance mechanisms is key to optimizing cancer treatment.